Skip to main content

Advertisement

SpringerLink
Log in

ISPMD consensus on the management of premenstrual disorders

  • Original Article
  • Published:
Archives of Women's Mental Health Aims and scope Submit manuscript

Abstract

The second consensus meeting of the International Society for Premenstrual Disorders (ISPMD) took place in London during March 2011. The primary goal was to evaluate the published evidence and consider the expert opinions of the ISPMD members to reach a consensus on advice for the management of premenstrual disorders. Gynaecologists, psychiatrists, psychologists and pharmacologists each formally presented the evidence within their area of expertise; this was followed by an in-depth discussion leading to consensus recommendations. This article provides a comprehensive review of the outcomes from the meeting. The group discussed and agreed that careful diagnosis based on the recommendations and classification derived from the first ISPMD consensus conference is essential and should underlie the appropriate management strategy. Options for the management of premenstrual disorders fall under two broad categories, (a) those influencing central nervous activity, particularly the modulation of the neurotransmitter serotonin and (b) those that suppress ovulation. Psychotropic medication, such as selective serotonin reuptake inhibitors, probably acts by dampening the influence of sex steroids on the brain. Oral contraceptives, gonadotropin-releasing hormone agonists, danazol and estradiol all most likely function by ovulation suppression. The role of oophorectomy was also considered in this respect. Alternative therapies are also addressed, with, e.g. cognitive behavioural therapy, calcium supplements and Vitex agnus castus warranting further exploration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington: The Association

  • Andersch B, Wendestam C, Hahn L, Ohman R (1986) Premenstrual complaints. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 5:39–49

    Article  Google Scholar 

  • Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T (2009) Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 34:1121–32

    Article  PubMed  CAS  Google Scholar 

  • Angst J, Sellaro R, Merikangas KR, Endicott J (2001) The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 104:110–16

    Article  PubMed  CAS  Google Scholar 

  • Bäckström T, Boyl H, Baird DT (1981) Persistence of symptoms of premenstrual tension in hysterectomized women. Br J Obstet Gynaec 88:530–536

    Article  Google Scholar 

  • Bäckström T, Sanders D, Leask RM, Davidson D, Warner P, Bancroft J (1983) Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to premenstrual syndrome. Psychosom Med 45:503–7

    PubMed  Google Scholar 

  • Bäckström T, Hansson-Malmström Y, Lindhe BA, Cavalli-Björkman B, Nordenström S (1992) Contraception 46:253–268

    Article  PubMed  Google Scholar 

  • Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, Andréen L, Ossewaarde L, Wingen GA, Turkmen S, Bengtsson SK (2011) Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 191:46–54

    Article  PubMed  CAS  Google Scholar 

  • Baker LJ, O’Brien PMS (2012) Potential strategies to avoid progestogen-induced premenstrual disorders. Menopause Int 18:73–76

    Article  PubMed  Google Scholar 

  • Björn I, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom G, Backstrom T (2003) Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 88:2026–30

    Article  PubMed  CAS  Google Scholar 

  • Borenstein JE, Dean BB, Yonkers KA, Endicott J (2007) Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 109:1068–75

    Article  PubMed  Google Scholar 

  • Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL (1994) Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 84:779–86

    PubMed  CAS  Google Scholar 

  • Brown J, O’Brien PMS, Marjoribanks J, Wyatt K (2009) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2, CD001396

    PubMed  Google Scholar 

  • Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH (2009) Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 78:6–15

    Article  PubMed  Google Scholar 

  • Casper RF, Hearn MT (1990) The effect of hysterectomy and bilateral oophorectomy on women with severe premenstrual syndrome. Am J Obstet Gynecol 162:105–9

    Article  PubMed  CAS  Google Scholar 

  • Casson P, Hahn PM, Van Vugt DA, Reid RL (1990) Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 162:99–105

    Article  PubMed  CAS  Google Scholar 

  • Chan AF, Mortola JF, Wood SH, Yen SS (1994) Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 84:1001–1005

    PubMed  CAS  Google Scholar 

  • Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL (2002a) Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 70:125–32

    Article  PubMed  Google Scholar 

  • Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S (2002b) Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 100:435–444

    Article  PubMed  CAS  Google Scholar 

  • Cronje WH, Vashisht A, Studd JW (2004) Hyseterctomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 19:2152–5

    Article  PubMed  CAS  Google Scholar 

  • Daley A (2009) Exercise and premenstrual symptomatology: a comprehensive review. J Women Health (Larchmt) 18:895–9

    Article  Google Scholar 

  • Dante G, Facchinetti F (2011) Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 32:42–51

    Article  PubMed  Google Scholar 

  • Deeny M, Hawthorn R, McKay HD (1991) Low dose danazol in the treatment of the premenstrual syndrome. Postgrad Med J 67:450–454

    Article  PubMed  CAS  Google Scholar 

  • Dennerstein L, Lehert P, Keung LS, Pal S, Choi D (2010a) Asian study of effects of premenstrual symptoms on activities of daily life. Menopause Int 16:146–151

    Article  PubMed  Google Scholar 

  • Dennerstein L, Lehert P, Bäckström TC, Heinemann K (2010b) The effect of premenstrual symptoms on activities of daily life. Fertil Steril 94:1059–64

    Article  PubMed  Google Scholar 

  • Dennerstein L, Lehert P, Heinemann K (2011) Global study of women’s experiences of premenstrual symptoms and their effects on daily life. Menopause Int 17:88–95

    Article  PubMed  Google Scholar 

  • Deuster P, Adera T, South-Paul J (1999) Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 8:122–28

    Article  PubMed  CAS  Google Scholar 

  • Dimmock PW, Wyatt KM, Jones PW, O'Brien PM (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome; a systematic review. Lancet 356:1131–6

    Article  PubMed  CAS  Google Scholar 

  • Elovainio M, Teperi J, Aalto AM (2007) Depressive symptoms as predictors of discontinuation of Levonorgestrel releasing intrauterine system. Int J Behav Med 14:70–5

    Article  PubMed  Google Scholar 

  • Endicott J, Nee J, Harrison W (2006) Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 9:41–9

    Article  PubMed  CAS  Google Scholar 

  • Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, Weiss E, Rothman DL, Krystal JH (2002) Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psych 59:851–8

    Article  CAS  Google Scholar 

  • Epperson CN, Steiner M, Hartlage SA, Eriksoon E, Schmidt P, Jones I, Yonkers KA (2012) Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psych 169:465–75

    Google Scholar 

  • Eriksson E, Hedberg MA, Andersch B, Sundblad C (1995) The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12:167–76

    Article  PubMed  CAS  Google Scholar 

  • Eriksson E, Ekman A, Sinclair S, Sörvik K, Ysander C, Mattson UB, Nissbrandt H (2008) Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 28:195–202

    Article  PubMed  CAS  Google Scholar 

  • Freeman EW, Sondheimer SJ, Rickels K (1997) Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 33:303–9

    PubMed  CAS  Google Scholar 

  • Freeman EW, Rickels K, Sondheimer SJ, Polansky M (1999) Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 56:932–9

    Article  PubMed  CAS  Google Scholar 

  • Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M (2001) Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 10:561–9

    Article  PubMed  CAS  Google Scholar 

  • Freeman EW, Stout AL, Endicott J, Spiers P (2002) Treatment of premenstrual syndrome with a carbohydrate-rich beverage. Int J Gynaecol Obstet 77:253–54

    Article  PubMed  CAS  Google Scholar 

  • Freeman EW, Sammel MD, Lin H, Rickels K, Sondheimer J (2011) Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstet Gynecol 118:1293–1300

    Article  PubMed  CAS  Google Scholar 

  • Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, Mirkin S, Constantine GD (2012) An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 85:437–45

    Article  PubMed  CAS  Google Scholar 

  • Graham CA, Sherwin BB (1992) A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 36:257–66

    Article  PubMed  CAS  Google Scholar 

  • Hahn PM, Van Vugt DA, Reid RL (1995) A randomized, placebo-controlled crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 20:193–209

    Article  PubMed  CAS  Google Scholar 

  • Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L (2002) Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 100:1219–1229

    Article  PubMed  CAS  Google Scholar 

  • Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003) The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28(suppl 3):1–23

    CAS  Google Scholar 

  • Halbreich U, Freeman EW, Rapkin AJ, Cohen LS, Grubb GS, Bergeron R, Smith L, Mirkin S, Constantine GD (2012) Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception 85:19–27

    Article  PubMed  CAS  Google Scholar 

  • Hammarbäck S, Bäckström T (1988) Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67:159–66

    Article  PubMed  Google Scholar 

  • Hammarbäck S, Bäckström T (1989) A demographic study in subgroups of women seeking help for premenstrual syndrome. Acta Obstet Gynecol Scand 68:247–53

    Article  PubMed  Google Scholar 

  • Hartlage SA, Freels A, Gotman N, Yonkers KA (2012) Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch Gen Psychiatry 69(3):300–5

    Article  PubMed  Google Scholar 

  • Howland RH (2007) Managing common side effects of SSRIs. Psychopharm 45:15–18

    Google Scholar 

  • Hunter MS, Ussher JM, Cariss M, Browne S, Jelley R, Katz M (2002) Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. J Psychosom Res 53:811–7

    Article  PubMed  Google Scholar 

  • Hussain SY, Massil JH, Matta WH, Shaw RW, O'Brien PM (1992) Buserelin in premenstrual syndrome. Gynecol Endocrinol 6:57–64

    Article  PubMed  CAS  Google Scholar 

  • Johnson SR, McChesney C, Bean JA (1988) Epidemiology of premenstrual symptoms in a nonclinical sample—I: prevalence, natural history and help-seeking behavior. J Repro Med 33:340–46

    CAS  Google Scholar 

  • Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR (2009) Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 105:158–61

    Article  PubMed  CAS  Google Scholar 

  • Kurshan N, Epperson CN (2006) Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Women Ment Health 9:1–14

    Article  CAS  Google Scholar 

  • Länden M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E (2007) Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 32:153–61

    Article  PubMed  CAS  Google Scholar 

  • Leather AT, Studd JWW, Watson NR, Holland EFN (1999) The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo controlled study. Gynecol Endocrinol 13:48–55

    Article  PubMed  CAS  Google Scholar 

  • Lopez LM, Kaptein AA, Helmerhorst FM (2009) Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. (2):CD006586

  • Lustyk MK, Gerrish WG, Shaver S, Keys SL (2009) Cognitive–behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Women Ment Health 12:85–96

    Article  Google Scholar 

  • Magos AL, Brincat M, Studd JWW (1986) Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral noresthisterone: placebo controlled study. BMJ 292:1629–33

    Article  PubMed  CAS  Google Scholar 

  • Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232:1004–1007

    Article  PubMed  CAS  Google Scholar 

  • Mellon SH (1994) Neurosteroids: biochemistry, modes of action, and clinical relevance. J Clin Endocrinol Metab 78:1003–8

    Article  PubMed  CAS  Google Scholar 

  • Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M (1994) Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 62:932–7

    PubMed  CAS  Google Scholar 

  • Miner C, Brown E, McCray S, Gonzales J, Wohlreich M (2002) Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 24:417–433

    Article  PubMed  CAS  Google Scholar 

  • Mitwally MF, Gotlieb L, Casper RF (2002) Prevention of bone loss and hypestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 9:236–41

    Article  PubMed  Google Scholar 

  • Moret C, Isaac M, Briley M (2009) Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharm 23:967–974

    Article  CAS  Google Scholar 

  • Muse KN, Cetel NS, Futterman LA, Yen SC (1984) The premenstrual syndrome. Effects of "medical ovariectomy". N Engl J Med 311:1345–9

    Article  PubMed  CAS  Google Scholar 

  • Nurnberg HG (2008) An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today 44:147–68

    Article  PubMed  CAS  Google Scholar 

  • O’Brien PMS, Abukhalil IEH (1999) Randomised controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase only danazol. Am J Obstet Gynecol 180:18–23

    Article  PubMed  Google Scholar 

  • O’Brien PMS, Bäckström T, Brown C, Dennerstein L, Endicott J, Neill et al (2011) Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD consensus. Arch Women Ment Health 14:13–21

    Article  Google Scholar 

  • Oinonen KA, Mazmanian D (2002) To what extent do oral contraceptives influence mood and affect? J Affect Disord 70:229–40

    Article  PubMed  CAS  Google Scholar 

  • Olsen RW, Sieghart W (2009) GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56:141–8

    Article  PubMed  CAS  Google Scholar 

  • Parry BL, Meliska CJ, Martínez LF, López AM, Sorenson DL, Hauger RL, Elliott JA (2008) Later, but not early, wake therapy reduces morning plasma melatonin: relationship to mood in premenstrual dysphoric disorder. Psychiatry Res 30:76–86

    Article  CAS  Google Scholar 

  • Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA (1997) Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 17:261–6

    Google Scholar 

  • Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA (2005) Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72:414–21

    Google Scholar 

  • Pincus SM, Alam S, Rubinow DR, Bhuvaneswar CG, Schmidt PJ (2011) Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res 45:386–94

    Article  PubMed  Google Scholar 

  • Ramacharan S, Love EJ, Fick GH, Goldfien A (1992) The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women. J Clin Epidemiol 45:377–81

    Article  Google Scholar 

  • Rivera-Tovar AD, Frank E (1990) Late luteal phase dysphoric disorder in young women. Am J Psychiatry 147:1634–36

    PubMed  CAS  Google Scholar 

  • Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U (2011) Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 8:2

    Article  PubMed  CAS  Google Scholar 

  • Royal College of Obstetricians and Gynaecologists (RCOG) (2007) Management of Premenstrual Syndrome (Green-top Guideline No. 48). http://www.rcog.org.uk/files/rcog-corp/uploaded-files/GT48ManagementPremensturalSyndrome.pdf. Accessed 10 May 2009

  • Sanders SA, Graham CA, Bass JL, Bancroft J (2001) A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 64:51–8

    Article  PubMed  CAS  Google Scholar 

  • Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R (1995) The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 86:520–8

    PubMed  CAS  Google Scholar 

  • Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR (1991) Lack on effect of induced menses of symptoms on women with premenstrual syndrome. N Engl J Med 324:1174–1179

    Article  PubMed  CAS  Google Scholar 

  • Schmidt PJ, Grover GN, Rubinow DR (1993) Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 50:467–73

    Article  PubMed  CAS  Google Scholar 

  • Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR (1998) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338:209–16

    Article  PubMed  CAS  Google Scholar 

  • Segebladh B, Borgström A, Nyberg S, Bixo M, Sundström-Poromaa I (2009) Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 201:139, e1-8

    Article  PubMed  CAS  Google Scholar 

  • Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borensstein J (2008) Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 111:1175–1182

    Article  PubMed  CAS  Google Scholar 

  • Shechter A, Boivin DB (2010) Sleep, hormones, and circadian rhythms throughout the menstrual cycle in healthy women and women with premenstrual dysphoric disorder. Int J Endocrinol 2010:259345

    PubMed  Google Scholar 

  • Smith RNH, Studd JWW, Zamblera D, Holland EFN (1995) A randomised comparison over 8 months of 100 mcgs and 200 mcg twice weekly doses in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 102:6475–84

    Google Scholar 

  • Soares C, Cohen L, Otto M, Harlow B (2001) Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard study of moods and cycles. J Women’s Health Gend Based Med 10:873–78

    Article  CAS  Google Scholar 

  • Steiner M, Pearlstein T (2000) Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 61(Suppl 12):17–21

    PubMed  Google Scholar 

  • Steiner M, Macdougall M, Brown E (2003) The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 6:203–209

    Article  CAS  Google Scholar 

  • Steiner M, Peer M, Palova E, Freeman EW, Macdougall M, Soares CN (2011) The premenstrual symptoms screening tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Women Ment Health 14:77–81

    Article  Google Scholar 

  • Studd J (2011) A guide to the treatment of depression women by hormones. Climacteric 14:637–42

    Article  PubMed  CAS  Google Scholar 

  • Sundblad C, Hedberg MA, Eriksson E (1993) Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9:133–145

    Article  PubMed  CAS  Google Scholar 

  • Sundstrom I, Nyberg S, Bixo M, Hammarbäck S, Bäckström T (1999) Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 78:891–9

    Article  PubMed  CAS  Google Scholar 

  • Sveindóttir H, Bäckström T (2000) Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 79:405–13

    Article  PubMed  Google Scholar 

  • Thys-Jacobs S, Starkey P, Bernstein D, Tian J (1998) Calcium carbonate and the premenstrual syndrome: effects of premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group Am J Obstet Gynecol 179:444–52

    Article  CAS  Google Scholar 

  • Watson NR, Studd JWW, Savvas M, Garnett T, Baber RJ (1989) Treatment of severe pre-menstrual syndrome with estradiol patched and cyclical oral noresthisterone. Lancet ii:730–734

    Article  Google Scholar 

  • West CP, Hillier H (1994) Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 9:1058–63

    PubMed  CAS  Google Scholar 

  • Whelan AM, Jurgens TM, Naylor H (2009) Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 16:407–29

    Google Scholar 

  • Wittchen HU, Becker E, Lieb R, Krause P (2002) Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32:119–132

    Article  PubMed  CAS  Google Scholar 

  • Woods NF, Most A, Dery GK (1982) Prevalence of perimenstrual symptoms. Am J Public Health 72:1257–64

    Article  PubMed  CAS  Google Scholar 

  • Wyatt KM, Dimmock PW, Jones PW, O’Brien PMS (1999) Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 318:1375–81

    Article  PubMed  CAS  Google Scholar 

  • Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM (2004) The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta-analysis. BJOG 111:585–93

    Article  PubMed  CAS  Google Scholar 

  • Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A (2005) Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106:492–501

    Article  PubMed  CAS  Google Scholar 

  • Yonkers KA, O’Brien PMS, Eriksson E (2008) Premenstrual syndrome. Lancet 371:1200–10

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Science and Technology in Medicine, Keele University, Stoke on Trent, UK

    Tracy Nevatte

  2. Academic Unit of Obstetrics and Gynaecology, University Hospital North Staffordshire, Keele University School of Medicine, Stoke on Trent, Staffordshire, UK

    Patrick Michael Shaughn O’Brien

  3. Umea Neurosteroid Research Center, Department of Clinical Sciences, Norrland University Hospital, Umea, Sweden

    Torbjorn Bäckström

  4. Department of Psychiatry, University of Tennessee Health Science Centre, Memphis, TN, USA

    Candace Brown

  5. Department of Obstetrics, University of Tennessee Health Science Centre, Memphis, TN, USA

    Candace Brown

  6. Department of Gynaecology, University of Tennessee Health Science Centre, Memphis, TN, USA

    Candace Brown

  7. Department of Psychiatry, University of Melbourne and National Ageing Research Institute, Melbourne, VIC, Australia

    Lorraine Dennerstein

  8. Department of Psychiatry, Columbia University, New York, NY, USA

    Jean Endicott

  9. Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    C. Neill Epperson

  10. Department of Obstetrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    C. Neill Epperson

  11. Department of Gynecology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    C. Neill Epperson

  12. Institute of Neuroscience and Physiology, Göteberg University, Göteberg, Sweden

    Elias Eriksson

  13. Department of Obstetrics/Gynecology, University of Pennsylvania, Philadelphia, PA, USA

    Ellen W. Freeman

  14. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

    Ellen W. Freeman

  15. State University of New York at Buffalo and WPA, New York, NY, USA

    Uriel Halbreich

  16. School of Clinical and Experimental Medicine, Birmingham Women’s Foundation Trust, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK

    Khalid Ismail

  17. Queen Charlotte’s and Chelsea and Westminster Hospitals, Imperial College London, London, UK

    Nicholas Panay

  18. Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA

    Teri Pearlstein

  19. Department of Obstetrics and Genecology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA

    Andrea Rapkin

  20. Queen’s University, Kingston, ON, Canada

    Robert Reid

  21. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    David Rubinow

  22. Section on Behavioral Endocrinology, National Institute of Mental Health, Bethesda, MD, USA

    Peter Schmidt

  23. Department of Psychiatry, Behavioural Neurosciences, Obstetrics and Gynaecology, St Joseph’s Healthcare, McMaster University, 301 James Street South, Hamilton, ON, L8P3B6, Canada

    Meir Steiner

  24. Department of Gynaecology, Chelsea and Westminster Hospital, London, UK

    John Studd

  25. Department of Women’s and Children’s Health, Obstetrics and Gynaecology, UU, 751 85, Uppsala, Sweden

    Inger Sundström-Poromaa

  26. Department of Psychiatry, New Haven, CT, USA

    Kimberly Yonkers

  27. Department of Obstetrics, New Haven, CT, USA

    Kimberly Yonkers

  28. Department of Gynaecology, New Haven, CT, USA

    Kimberly Yonkers

Authors
  1. Tracy Nevatte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Michael Shaughn O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Torbjorn Bäckström
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Candace Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lorraine Dennerstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean Endicott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Neill Epperson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elias Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ellen W. Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Uriel Halbreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Khalid Ismail
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nicholas Panay
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Teri Pearlstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Andrea Rapkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Robert Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. David Rubinow
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Peter Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Meir Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. John Studd
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Inger Sundström-Poromaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Kimberly Yonkers
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Consensus Group of the International Society for Premenstrual Disorders

Corresponding author

Correspondence to Tracy Nevatte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nevatte, T., O’Brien, P.M.S., Bäckström, T. et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 16, 279–291 (2013). https://doi.org/10.1007/s00737-013-0346-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00737-013-0346-y

Keywords

Search

Navigation